SCHEMBL3154146

SCHEMBL3154146

Cn1nnc(NS(=O)(=O)c2ccc(C(=O)NCc3ccc(C(F)(F)F)cc3)cc2)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 2/20 0.59
MAPT P10636 3/20 0.56
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
LMNA P02545 1/20 0.56
LSS P48449 1/20 0.50
RORC P51449 3/20 0.49
EPHX2 P34913 4/20 0.49
TDP1 Q9NUW8 1/20 0.49
PPARA Q07869 2/20 0.48
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
NR1H4 Q96RI1 2/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
PPARG P37231 1/20 0.46
MAPK14 Q16539 1/20 0.46
NPC1 O15118 1/20 0.46
TP53 P04637 1/20 0.46
RECQL P46063 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3168731 0.84 SCN3A (0.62) SCN3AMAPTMEN1KMT2ALMNA
SCHEMBL3167830 0.82 SCN3A (0.59) SCN3AMAPTMEN1KMT2ALMNA
SCHEMBL3167975 0.82 SCN3A (0.59) SCN3AMAPTMEN1KMT2ALMNA
SCHEMBL3159534 0.79 SCN3A (0.61) SCN3AMAPTMEN1KMT2ALMNA
SCHEMBL3164167 0.78 SCN3A (0.57) SCN3AMAPTMEN1KMT2ALMNA
SCHEMBL3172289 0.78 SCN3A (0.67) SCN3AMAPTMEN1KMT2ALMNA
SCHEMBL12010898 0.77 MAPT (0.80) SCN3AMAPTMEN1KMT2ALMNA
SCHEMBL3174089 0.77 SCN3A (0.64) SCN3AMAPTMEN1KMT2ALMNA
SCHEMBL3153875 0.77 SCN3A (0.61) SCN3AMAPTMEN1KMT2ALMNA
SCHEMBL3159876 0.76 SCN3A (0.71) SCN3AMAPTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN3A 13/4885MAPT 2938/4885MEN1 4729/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN3A 13/4885MAPT 2938/4885MEN1 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.